If you would like to submit a blog post for consideration, please email firstname.lastname@example.org
In this month’s skin cancer update, Professor Giuseppe Argenziano discusses melanoma that arise within pre-existing congenital naevi.
The risk of melanoma arising out of large congenital naevi in a person’s lifetime is 1 in 10. The risk in intermediate congenital naevi is 1 in 200 and the risk in small congenital naevi is 1 in 200,000. Thus, the risk increases with the size of the naevus. Continue reading “Skin Cancer Update with Prof Giuseppe Argenziano [April 2018]”
This week we have an interesting case from Dr Colin Armstrong. An elderly gentleman presented for a skin check, and a very obvious dark lesion on the lower back was noted.
Please review and describe the clinical and dermoscopic image. What is your evaluation, and proposed next step/s?
This week we have an engaging case from Dr Dorothy Dowd. A mid thirties gentleman obviously has multiple mole syndrome from the image below. So, two issues:
- What is your assessment of the 2 lesions Dr Dowd shows here?
- How do you manage these patients in your practice?
In this month’s skin cancer update, Associate Professor Giuseppe Argenziano discusses vulvar mucosal lesions. These pigmented lesions can be difficult to manage because they often look very irregular and fit the ABCD criteria for melanoma.
Giuseppe explains that with vulvar lesions, we should avoid applying the same rules that typically apply to the rest of the body concerning the clinical diagnosis of melanomas. Continue reading “Skin Cancer Update with A/Prof Giuseppe Argenziano [March 2018]”
Chemotherapy could become a thing of the past for up to two thirds of cancer patients, as the federal government considers subsidising new immunotherapy treatments.
Immunotherapy treatments Optivo and Keytruda are already subsidised by the government for the treatment of patients with melanoma, lung cancer and kidney cancer. Seeking subsidisation is a slow process that has denied treatment to patients with other cancers who cannot afford therapy. Continue reading “Immunotherapy Replacing Chemotherapy in Melanoma Treatment”
This week we have an engaging case from Dr Tim Aung. An 80-year-old male with past history of melanoma and NMSC. The below shown lesion was noted on regular skin check.
Please review and describe the clinical and dermoscopic image. What is your evaluation, and proposed next step/s? Continue reading “Case discussion: How would you treat this patient? [26 February]”
If all Australians regularly applied sunscreen, the burden of melanoma could be reduced by up to 34 per cent by 2031, according to a study by the QIMR Berghofer Medical Research Institute.
In a study published in the British Journal of Dermatology, researchers predicted the likely impact of regular sunscreen use on melanoma rates. They found that 28,071 fewer melanomas would be diagnosed in Australia over the next 13 years if everyone frequently wore sunscreen. Continue reading “Regular Sunscreen Use Could Reduce Melanoma Rates by a Third”
In this month’s skin cancer update, Associate Professor Guiseppe Argenziano explains some important rules to avoid missing a melanoma. Giuseppe says it is possible for any doctor to miss a melanoma, but there are a set of rules we can apply to every scenario to decrease the likelihood of this happening.
Guiseppe gives the example of two patients whose moles looked dermoscopically similar, yet one lesion was benign and the other was a melanoma. How can doctors avoid making the wrong decision in a case like this?
This week we have an interesting case from Dr Slavko Doslo. Elderly male, reports non healing ulcer being there for several weeks.
Please review and describe the clinical and dermoscopic images. What is your evaluation, and differential diagnosis? What would you do?
Is it necessary to update guidelines for genetic testing for melanoma in countries with low to moderate incidence?
Genetic testing for melanoma-prone mutation in France (a country with low to moderate incidence of melanoma) is proposed in cases with two invasive cutaneous melanomas in the same patient, or in first- or second-degree relatives. In preclinical studies, these rules led to disclosure of mutation(s) in more than 10 per cent of these families, the threshold widely accepted to justify genetic testing for cancers. Continue reading “Guidelines for Genetic Testing for Melanoma”